Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Acute Myeloid Leukemia
100%
Novel Therapeutic Targets
100%
FLT3-ITD
100%
Therapeutic Biomarkers
100%
Follistatin
100%
Leukemia
50%
Leukemia Patients
37%
Engraftment
25%
FMS-like Tyrosine Kinase 3 (FLT3)
25%
Overexpression
12%
Poor Response
12%
Antisense Oligomers
12%
Clonogenicity
12%
Knock-in Mouse Model
12%
Treatment Outcome
12%
CCL5
12%
Conventional Treatment
12%
Zebrafish Embryo
12%
Transgenic Zebrafish
12%
Ectopic Expression
12%
Short Hairpin RNA (shRNA)
12%
Specific Targeting
12%
Xenograft Mice
12%
Early Embryonic Development
12%
Adverse Outcomes
12%
Internal Tandem Duplication
12%
FLT3 Inhibitor
12%
Cas9 Protein
12%
Patient-derived Xenograft
12%
Clinical Response
12%
Acute Myeloid Leukemia Cells
12%
Blast Count
12%
IL2RA
12%
Xenotransplantation Model
12%
Axis Duplication
12%
Morphogen
12%
Dorsalization
12%
Quizartinib
12%
Medicine and Dentistry
Biological Marker
100%
Acute Myeloid Leukemia
100%
Follistatin
100%
Leukemia
42%
Engraftment
28%
Clustered Regularly Interspaced Short Palindromic Repeat
14%
Morphology
14%
Upregulation
14%
Xenograft
14%
Adverse Outcome
14%
Antisense
14%
Embryo Development
14%
Leukemia Cell
14%
Xenotransplantation
14%
Short Hairpin RNA
14%
CD135 Antigen
14%
Cas9
14%
Quizartinib
14%
Ectopic Expression
14%
Morphogen
14%
Pharmacology, Toxicology and Pharmaceutical Science
Biological Marker
100%
Follistatin
100%
Acute Myeloid Leukemia
100%
Leukemia
42%
Zebra Fish
14%
Transgenic Zebrafish
14%
Adverse Outcome
14%
Short Hairpin RNA
14%
CD135 Antigen
14%
Quizartinib
14%
Morphogen
14%
Immunology and Microbiology
Myeloid
100%
Engraftment
28%
Xenograft
14%
Antisense
14%
CRISPR/Cas9
14%
Leukemia Cell
14%
Upregulation
14%
Zebra Fish
14%
Embryo Development
14%
Morphology
14%
Clonogenesis
14%
CCL5
14%
CD135 Antigen
14%
Transgenic Zebrafish
14%
Xenotransplantation
14%
Ectopic Expression
14%
Morphogen
14%